MAM
Triptii Dimri, the face of One GOA: The 130+ acre 5 star gated branded land development by The House of Abhinandan Lodha
Mumbai: The House of Abhinandan Lodha (HoABL) proudly introduces a groundbreaking endeavor in the heart of Goa – One GOA, an expansive 130+ acre, 5-star luxury plotted development nestled in Bicholim. This exclusive project redefines opulence, boasting a host of amenities designed to offer an unmatched experience. At its centerpiece lies a magnificent 5-star hotel, housing 50 to 100 opulent rooms, seamlessly integrated with a sprawling 40,000 sq. ft. clubhouse. Set against the backdrop of a picturesque man-made sea and beach, One GOA is a mere 40-minute drive from the newly inaugurated MOPA airport, ensuring convenient access for discerning travelers.
Highlighting this project’s commitment to embodying class, integrity and a beautiful vision blending form, aesthetics, and function, Triptii Dimri, Bollywood’s upcoming sensation and the country’s heartthrob, has become the face of One GOA for HoABL.
One of the most captivating features of this development is the partnership with Enzyme, a globally renowned architectural firm celebrated for its expertise in crafting luxurious spaces. Together, they have conceived a lavish 3-tiered clubhouse sprawled across 40,000 sq. ft., seamlessly managed by the prestigious hotel. Within this exclusive enclave, patrons will discover a chic discotheque, a tantalizing multi-cuisine restaurant, and a curated selection of amenities including a state-of-the-art gym managed by a prestigious fitness alliance, an inviting coffee shop, and a boutique retail plaza catering to every indulgence.
The crown jewel of One GOA is its expansive 23-acre central zone, meticulously designed to encapsulate the essence of Goa’s coastal charm. From pristine beaches to charming pergolas, gazebo zones, and sports facilities, every corner exudes an irresistible allure, harmonizing with the natural ecosystem thanks to Enzyme’s masterful touch.
With Goa’s strategic location poised for significant growth, propelled by forthcoming infrastructural projects like the NH-66 New Mumbai-Goa Highway and Nagpur-Shaktipeeth Highway, the region is primed to become a hotbed for investment opportunities. One GOA emerges as a beacon of this transformation, offering a holistic experience that encapsulates the vibrant spirit of Goa.
Moreover, with the imminent completion of the Delhi-Mumbai Expressway, inter-city connectivity is set to undergo a paradigm shift, ushering in a new era of prosperity and growth. This augurs well for the region, promising increased tourism inflows and heightened demand for commercial and hospitality services.
In its commitment to sustainability, One GOA proudly boasts a carbon-negative status, underscored by the plantation of over 3,000 trees representing 30+ diverse species, further enhancing its eco-friendly credentials.
As Goa evolves into an investor’s paradise, One GOA stands as a testament to luxury living, offering a seamless blend of vibrant nightlife, gastronomic delights, entertainment, recreation, and serene waterfront experiences, all within a single captivating destination.
The House of Abhinandan Lodha CEO Samujjwal Ghosh states, “Our commitment to redefining the real estate landscape is evident in every facet of One GOA. From the magnificent clubhouse amidst lush greenery to the internationally acclaimed discotheque and tantalizing multi-cuisine restaurant, every aspect has been meticulously crafted to offer an unparalleled experience.
Furthermore, with upcoming infrastructural developments, the region is poised for exponential growth, with MOPA airport geared to fulfil 3.3 cr passengers travelling inbound annually. A great situation for Goa – with a projected GDP of Rs 1.08 lac crores by 2025.
The House of Abhinandan Lodha’s mission to offer land in the most strategic locations and offer its patrons a richer life underscores the organisation’s commitment to catalysing growth and prosperity. This large luxury development in Goa redefines luxury consumption. With a diverse portfolio of investment opportunities across strategic locations in India, this is a journey towards redefining luxury living and investment.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
